Influenza surveillance and response remains an ongoing, and changing, challenge-and pandemic preparedness goes well beyond stockpiling vaccines, noted speakers at IDWeek 2015’s closing plenary session.
IDWeek 2015: Adult Infectious Disease
Tigecycline used as adjunctive therapy for severe Clostridium difficile-associated diarrhea (CDAD) led to higher rates of colectomy and higher mortality, according to results of a multicenter study presented by Candace Marr, DO, from the Catholic Health System and The State University of New York at Buffalo, Buffalo, NY, at IDWeek 2015.
Treatment with fluoroquinolones was definitely associated with subsequent tendon ruptures, and was found to be a possible contributor in aortic aneurysms, presented Nick Daneman, MD, MSc, from the University of Toronto, Ontario, Canada, at IDWeek 2015.
There was no statistically significant difference in clinical outcomes between patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia who were treated with linezolid and those treated with vancomycin except mortality, reported ManShan Celica Tong, PharmD, MPH, from Medical University of South Carolina, Charleston, SC, at IDWeek 2015.
The combination of ceftolozane and tazobactam showed comparable outcomes to levofloxacin in the treatment of complicated pyelonephritis, according to results from the Phase 3 ASEPCT-cUTI trial presented at IDWeek 2015.
Dual therapy with vancomycin plus a beta-lactam antibiotic may reduce surgical site infections (SSI) by up to 63%, a study presented at IDWeek 2015 has found, with the strongest association seen in cardiac procedures.
Administering a three-Lactobacillus spp. probiotic to patients undergoing antibiotic therapy might reduce the frequency of nosocomial Clostridium difficile infections (CDI), suggest findings from a single-institution study reported at IDWeek 2015.
Renal impairment does not appear to affect the safety or clinical efficacy of tedizolid compared to linezolid among adults treated for skin and skin structure infections (ABSSSI), according to a post-hoc analysis of data from two randomized, controlled phase 3 clinical trials, reported at IDWeek 2015.
Patients with good prognoses suffer longer hospitalizations when they receive inappropriate empirical antimicrobial therapy for E. coli and other gram-negative bloodstream infections, according to study findings reported at IDWeek 2015.
High-dose oral vancomycin does not improve clinical outcomes over 125mg low dose vancomycin therapy among adult patients with nosocomial Clostridium difficile infection (CDI), according to retrospective study findings reported at IDWeek 2015
- Loading...
Want to read more?
Please login or register first to view this content.
